{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:00:30Z","timestamp":1792479630379,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13387-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:02:11Z","timestamp":1776715331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vonoprazan versus rabeprazole in dual therapy with amoxicillin for Helicobacter pylori eradication: a prospective, multicenter, open-label, randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Haocheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"13387_CR1","doi-asserted-by":"publisher","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment[J]. Chin Med J (Engl). 2022;135(24):2899\u2013910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546.","DOI":"10.1097\/CM9.0000000000002546"},{"key":"13387_CR2","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report[J]. Gut. 2022;71(9):1724\u201362.","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"13387_CR3","doi-asserted-by":"publisher","unstructured":"Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol. 2023;8(6):553\u201364.https:\/\/doi.org\/10.1016\/S2468-1253(23)00070-5.","DOI":"10.1016\/S2468-1253(23)00070-5"},{"key":"13387_CR4","doi-asserted-by":"publisher","unstructured":"Ren S, Cai P, Liu Y, et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol. 2022;37(3):464\u201370. https:\/\/doi.org\/10.1111\/jgh.15751.","DOI":"10.1111\/jgh.15751"},{"key":"13387_CR5","doi-asserted-by":"publisher","unstructured":"Zeng S, Kong Q, Wu X, et al. Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis[J]. Int J Antimicrob Agents. 2024;64(5):107325. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107325.","DOI":"10.1016\/j.ijantimicag.2024.107325"},{"key":"13387_CR6","doi-asserted-by":"publisher","unstructured":"Shao QQ, Yu XC, Yu M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial[J]. Helicobacter. 2022;27(2):e12876. https:\/\/doi.org\/10.1111\/hel.12876.","DOI":"10.1111\/hel.12876"},{"key":"13387_CR7","doi-asserted-by":"crossref","unstructured":"Tai WC, Wu IT, Wang HM, et al. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan[J]. J Microbiol Immunol Infect. 2024;57(4):601\u2013810. https:\/\/doi.org\/10.16\/j.jmii.2024.02.009.","DOI":"10.1016\/j.jmii.2024.02.009"},{"key":"13387_CR8","doi-asserted-by":"publisher","unstructured":"Guan JL, Hu YL, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial[J]. Pharmacotherapy. 2022;42(3):224\u201332 https:\/\/doi.org\/10.1002\/phar.2662.","DOI":"10.1002\/phar.2662"},{"issue":"1","key":"13387_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","volume":"54","author":"C Shen","year":"2022","unstructured":"Shen C, Li C, Lv M, et al. The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas[J]. Ann Med. 2022;54(1):426\u201335. https:\/\/doi.org\/10.1080\/07853890.2022.2031269.","journal-title":"Ann Med"},{"key":"13387_CR10","doi-asserted-by":"publisher","unstructured":"Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis[J]. Helicobacter. 2020;25(4):e12692. https:\/\/doi.org\/10.1111\/hel.12692.","DOI":"10.1111\/hel.12692"},{"key":"13387_CR11","doi-asserted-by":"publisher","unstructured":"Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease[J]. Curr Opin Gastroenterol. 2019;35(4):344\u201355. https:\/\/doi.org\/10.1097\/MOG.0000000000000543.","DOI":"10.1097\/MOG.0000000000000543"},{"key":"13387_CR12","doi-asserted-by":"publisher","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study[J]. Gut. 2016;65(9):1439\u201346. https:\/\/doi.org\/10.1136\/gutjnl-2015-311304.","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"13387_CR13","doi-asserted-by":"publisher","unstructured":"Zuberi BF, Ali FS, Rasheed T, et al. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for helicobacter pylori eradication: a randomized control trial[J]. Pak J Med Sci. 2022;38(4Part-II):965\u2013969. https:\/\/doi.org\/10.12669\/pjms.38.4.5436.","DOI":"10.12669\/pjms.38.4.5436"},{"key":"13387_CR14","doi-asserted-by":"publisher","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan[J]. Gut. 2020;69(6):1019\u201326. https:\/\/doi.org\/10.1136\/gutjnl-2019-319954.","DOI":"10.1136\/gutjnl-2019-319954"},{"key":"13387_CR15","doi-asserted-by":"publisher","unstructured":"Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of helicobacter pylori[J]. Digestion. 2020;101(6):743\u201351. https:\/\/doi.org\/10.1159\/000502287.","DOI":"10.1159\/000502287"},{"key":"13387_CR16","doi-asserted-by":"publisher","unstructured":"Gao W, Teng G, Wang C, et al. Eradication rate and safety of a simplified rescue therapy: 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China[J]. Helicobacter. 2022;27(5):e12918. https:\/\/doi.org\/10.1111\/hel.12918.","DOI":"10.1111\/hel.12918"},{"key":"13387_CR17","unstructured":"Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China[J]. Am J Cancer Res. 2021;11(10):5027\u201337."},{"key":"13387_CR18","doi-asserted-by":"publisher","unstructured":"Graham DY. Crises in antimicrobial stewardship: misuse of clarithromycin for helicobacter pylori therapy[J]. Pharmacoepidemiology. 2024;3(1):82\u201393. https:\/\/doi.org\/10.3390\/pharma3010006.","DOI":"10.3390\/pharma3010006"},{"key":"13387_CR19","doi-asserted-by":"publisher","unstructured":"Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus[J]. Gut. 2020;69(12):2093\u2013112. https:\/\/doi.org\/10.1136\/gutjnl-2020-322368.","DOI":"10.1136\/gutjnl-2020-322368"},{"key":"13387_CR20","doi-asserted-by":"publisher","unstructured":"Ju KP, Kong QZ, Li YY, et al. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis[J]. Helicobacter. 2024;29(1):e13054. https:\/\/doi.org\/10.1111\/hel.13054.","DOI":"10.1111\/hel.13054"},{"key":"13387_CR21","doi-asserted-by":"publisher","unstructured":"Peng X, Chen HW, Wan Y, et al. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study[J]. Clin Exp Med. 2023;23(7):4011\u20139. https:\/\/doi.org\/10.1007\/s10238-023-01074-5.","DOI":"10.1007\/s10238-023-01074-5"},{"key":"13387_CR22","doi-asserted-by":"publisher","unstructured":"Peng R, Cai P, Zhang Z, et al. Efficacy of three amoxicillin doses in vonoprazan dual therapy for helicobacter pylori eradication: a randomized noninferiority trial[J]. Helicobacter. 2025;30(3):e70050. https:\/\/doi.org\/10.1111\/hel.70050.","DOI":"10.1111\/hel.70050"},{"key":"13387_CR23","doi-asserted-by":"publisher","unstructured":"Zhou BG, Jiang X, Ding YB, et al. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis[J]. Helicobacter. 2024;29(1):e13040. https:\/\/doi.org\/10.1111\/hel.13040.","DOI":"10.1111\/hel.13040"},{"issue":"12","key":"13387_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","volume":"58","author":"YY Han","year":"2023","unstructured":"Han YY, Zhou L, Hu YL, et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study[J]. J Gastroenterol. 2023;58(12):1167\u201377. https:\/\/doi.org\/10.1007\/s00535-023-02042-2.","journal-title":"J Gastroenterol"},{"key":"13387_CR25","doi-asserted-by":"publisher","unstructured":"Sun LN, Cao Y, Li YQ, et al. Impact of gastric H(+)\/K(+)-ATPase rs2733743 on the intragastric pH-values of dexlansoprazole injection in Chinese subjects[J]. Front Pharmacol. 2017;8:670. https:\/\/doi.org\/10.3389\/fphar.2017.00670.","DOI":"10.3389\/fphar.2017.00670"},{"key":"13387_CR26","doi-asserted-by":"crossref","unstructured":"Qi F, Zhu L, Li N, et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole[J]. Int J Antimicrob Agents. 2017;49(4):403\u2013910. https:\/\/doi.org\/10.16\/j.ijantimicag.2016.11.025.","DOI":"10.1016\/j.ijantimicag.2016.11.025"},{"issue":"1","key":"13387_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/00365521.2024.2444477","volume":"60","author":"H Waldum","year":"2025","unstructured":"Waldum H, Fossmark R. Eradication of Helicobacter pylori by a potassium-competitive acid blocker alone?[J]. Scand J Gastroenterol. 2025;60(1):10\u20132. https:\/\/doi.org\/10.1080\/00365521.2024.2444477.","journal-title":"Scand J Gastroenterol"},{"key":"13387_CR28","doi-asserted-by":"publisher","unstructured":"He S, He X, Duan Y, et al. The impact of diet, exercise, and sleep on Helicobacter pylori infection with different occupations: a cross-sectional study[J]. BMC Infect Dis. 2024;24(1):692. https:\/\/doi.org\/10.1186\/s12879-024-09505-8.","DOI":"10.1186\/s12879-024-09505-8"},{"key":"13387_CR29","doi-asserted-by":"publisher","unstructured":"Lee JW, Kim N, Nam RH, et al. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance[J]. Helicobacter. 2021;26(5):e12844. https:\/\/doi.org\/10.1111\/hel.12844.","DOI":"10.1111\/hel.12844"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13387-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:35:57Z","timestamp":1780446957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13387-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13387"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13387-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a prospective, multicenter, open-label, randomized controlled trial. It was approved by the Medical Ethics Committee of Nanjing First Hospital Affiliated to Nanjing Medical University (Approval No. KY20240123-21). The trial was conducted in accordance with the Declaration of Helsinki, using commercially available and widely adopted medications. All participants were fully informed of potential risks and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1069"}}